SCOR separates trial tested GLP-1 drugs from untested peptides like BPC-157 and tracks the FDA's shifting compounding rules on 19 peptides since 2023.
Recap by typeshit. Full story at SCOR.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Cyprus Mail reports that Mounjaro is being added to Gesy coverage, both for diabetes and for adults with obesity.
The $0 benefit needs a new prior approval and still excludes weight loss use. Enrollment for about 1.6 million US associates runs through Nov. 6.
Loading…